Zoetis Inc. $ZTS Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.5% during the second quarter, Holdings Channel reports. The fund owned 1,188,124 shares of the company’s stock after selling 124,565 shares during the quarter. California Public Employees Retirement System’s holdings in Zoetis were worth $185,288,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cary Street Partners Financial LLC boosted its stake in shares of Zoetis by 0.4% during the 2nd quarter. Cary Street Partners Financial LLC now owns 99,006 shares of the company’s stock worth $15,440,000 after purchasing an additional 389 shares during the last quarter. Cerity Partners LLC raised its position in shares of Zoetis by 32.0% in the second quarter. Cerity Partners LLC now owns 325,061 shares of the company’s stock valued at $50,693,000 after buying an additional 78,738 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in shares of Zoetis by 33.1% during the second quarter. Gamco Investors INC. ET AL now owns 15,690 shares of the company’s stock valued at $2,447,000 after buying an additional 3,901 shares during the period. Morton Community Bank boosted its position in Zoetis by 9.2% during the second quarter. Morton Community Bank now owns 19,154 shares of the company’s stock worth $2,987,000 after acquiring an additional 1,610 shares during the last quarter. Finally, Avestar Capital LLC grew its stake in Zoetis by 46.3% in the 2nd quarter. Avestar Capital LLC now owns 3,632 shares of the company’s stock worth $566,000 after acquiring an additional 1,150 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.4%

ZTS stock opened at $118.69 on Monday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market cap of $52.31 billion, a price-to-earnings ratio of 19.98, a PEG ratio of 2.46 and a beta of 0.97. The business has a fifty day simple moving average of $133.77 and a 200-day simple moving average of $147.57. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $181.85.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the firm earned $1.58 earnings per share. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st were issued a dividend of $0.50 per share. The ex-dividend date was Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s payout ratio is presently 33.67%.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Finally, BTIG Research restated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.